2023年 新着論文 67 バイオインフォマティクス分野から論文が発表されました

Latent inter-organ mechanism of idiopathic pulmonary fibrosis unveiled by a generative computational approach

Sci Rep. 2023 Dec 11;13(1):21981. doi: 10.1038/s41598-023-49281-0.

Authors

Satoshi Kozawa #  1   2 Kengo Tejima #  1   2 Shunki Takagi #  1   2 Masataka Kuroda  3   4 Mari Nogami-Itoh  3 Hideya Kitamura  5 Takashi Niwa  5 Takashi Ogura  5 Yayoi Natsume-Kitatani  3   6 Thomas N Sato  7   8   9

Affiliations

  • 1 Karydo TherapeutiX, Inc., 2-2-2 Hikaridai, Seika-Cho, Soraku-Gun, Kyoto, 619-0288, Japan.
  • 2 The Thomas N. Sato BioMEC-X Laboratories, Advanced Telecommunications Research Institute International (ATR), Kyoto, Japan.
  • 3 National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
  • 4 Mitsubishi Tanabe Pharma Corporation, Kanagawa, Japan.
  • 5 Kanagawa Cardiovascular and Respiratory Center, Kanagawa, Japan.
  • 6 Institute of Advanced Medical Sciences, Tokushima University, Tokushima, Japan.
  • 7 Karydo TherapeutiX, Inc., 2-2-2 Hikaridai, Seika-Cho, Soraku-Gun, Kyoto, 619-0288, Japan. island1005@gmail.com.
  • 8 The Thomas N. Sato BioMEC-X Laboratories, Advanced Telecommunications Research Institute International (ATR), Kyoto, Japan. island1005@gmail.com.
  • 9 V-iCliniX Laboratory, Nara Medical University, Nara, Japan. island1005@gmail.com.
# Contributed equally.

Free PMC article

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive disease characterized by complex lung pathogenesis affecting approximately three million people worldwide. While the molecular and cellular details of the IPF mechanism is emerging, our current understanding is centered around the lung itself. On the other hand, many human diseases are the products of complex multi-organ interactions. Hence, we postulate that a dysfunctional crosstalk of the lung with other organs plays a causative role in the onset, progression and/or complications of IPF. In this study, we employed a generative computational approach to identify such inter-organ mechanism of IPF. This approach found unexpected molecular relatedness of IPF to neoplasm, diabetes, Alzheimer’s disease, obesity, atherosclerosis, and arteriosclerosis. Furthermore, as a potential mechanism underlying this relatedness, we uncovered a putative molecular crosstalk system across the lung and the liver. In this inter-organ system, a secreted protein, kininogen 1, from hepatocytes in the liver interacts with its receptor, bradykinin receptor B1 in the lung. This ligand-receptor interaction across the liver and the lung leads to the activation of calmodulin pathways in the lung, leading to the activation of interleukin 6 and phosphoenolpyruvate carboxykinase 1 pathway across these organs. Importantly, we retrospectively identified several pre-clinical and clinical evidence supporting this inter-organ mechanism of IPF. In conclusion, such feedforward and feedback loop system across the lung and the liver provides a unique opportunity for the development of the treatment and/or diagnosis of IPF. Furthermore, the result illustrates a generative computational framework for machine-mediated synthesis of mechanisms that facilitates and complements the traditional experimental approaches in biomedical sciences.

Conflict of interest statement

T.N.S., S.K., K.T., S.T. are employees of Karydo TherapeutiX, Inc. No other author possesses competing interest.

Full text links